Answers are grounded in this paper and cite their sources.
Plant homeodomain finger protein 8 (PHF8), a JmjC domain-containing lysine demethylase, serve as a critical epigenetic regulator of tumor progression. By erasing repressive histone methylation marks and modulating non-histone substrates TOPBP1 and YY1, PHF8 remodels oncogenic transcriptional networks to drive core cancer hallmarks, including aberrant proliferation, epithelial-mesenchymal transition (EMT), immune evasion, metabolic reprogramming, and inflammatory microenvironments. Aberrant PH8 upregulation across diverse human cancers consistently correlates with unfavorable clinical outcomes, establishing PHF8 as a promising druggable epigenetic target. This review systematically delineates the structural characteristics, substrates profiles, and multifaceted oncogenic mechanisms of PHF8 in malignancies, ranging from early non-selective JmjC inhibitors (daminozide, GSK-J4, etc. ) to newly identified selective small-molecule antagonist and PHD finger-targeting cyclic peptides represented by OC9. Major drawbacks of existing compounds include insufficient selectivity against homologous KDM7A and incomplete suppression of PHF8 non-catalytic oncogenic roles. We further discuss actionable strategies: structural-guided drug design, natural product optimization, peptide modification and PROTAC-mediated protein degradation. Combinations of PHF8 modulators with clinical drugs are also highlighted to overcome drug resistance. This overview provides a refined framework to facilitate further basic research and translational development of PHF8-targeted anticancer therapeutics.
No takes yet. Share an insight, caveat, or question.
Ke et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: